You might be interested in
Health & Biotech
Health Check: More biotechs change their names, but will they smell just as sweet?
Health & Biotech
‘One straightforward request’: Neurizon buoyant on FDA clarity
Health & Biotech
News
Stockhead’s Top 10 at 10, published at 10.15am each trading day, highlights the best (and worst) performing ASX small caps in morning trade using live data.
It’s a short, sharp update to help frame the trading day by showing the biggest movers in percentage terms.
The market opens at 10am (eastern time) and the data is taken at 10:15am, once every ASX stock has commenced trading.
Stocks highlighted in yellow have made market-moving announcements (click headings to sort).
Code | Company | Price | % | Volume |
NPM | Newpeak Metals | 0.0015 | 50 | 3474919 |
IDZ | Indoor Skydive Aust | 0.035 | 35 | 5471062 |
OEX | Oilex Ltd | 0.004 | 33 | 377481 |
WOO | Wooboard Tech Ltd | 0.002 | 33 | 1255826 |
ANL | Amani Gold Ltd | 0.0025 | 25 | 166666 |
MLS | Metals Australia | 0.0025 | 25 | 7737361 |
EFE | Eastern Iron | 0.068 | 24 | 22603434 |
HMD | Heramed Limited | 0.32 | 21 | 583287 |
AFW | Applyflow Limited | 0.007 | 17 | 285714 |
SMX | Security Matters | 0.335 | 16 | 45731 |
Indoor Skydive Australia Group (ASX:IDZ) rose after announcing it appointed a new director – in defence industry executive Mark Smethurst.
Eastern Iron (ASX:EFE) unveiled a strategic partnership agreement with Sichuan Yahua Industrial Group to provide a framework for future collaboration on the acquisition and development of lithium projects.
Code | Company | Price | % | Volume |
PCL | Pancontinental Energ | 0.001 | -33 | 268233 |
CCE | Carnegie Cln Energy | 0.002 | -20 | 1189710 |
OVT | Ovato Limited | 0.002 | -20 | 125000 |
PAA | Pharmaust Limited | 0.105 | -13 | 1569808 |
XST | Xstate Resources | 0.004 | -11 | 855384 |
FGL | Frugl Group Limited | 0.026 | -10 | 209090 |
PRM | Prominence Energy | 0.009 | -10 | 1091600 |
K2F | K2Fly Ltd | 0.28 | -10 | 83000 |
IBG | Ironbark Zinc Ltd | 0.039 | -9 | 837395 |
CYQ | Cycliq Group Ltd | 0.02 | -9 | 500000 |
PharmAust (ASX:PAA) fell despite announcing the expansion of its canine Phase 2b lymphoma studies into New Zealand.